EUVIMEDEUVIMED entdecken
Crossref

Inflammatory Rhabdomyoblastic Tumor: Clinicopathologic and Molecular Analysis of 13 Cases

Toru Odate, Kaishi Satomi, Takashi Kubo, Yuko Matsushita, Toshihide Ueno, Akira Kurose, Kohei Shomori, Tokiko Nakai, Reiko Watanabe, Keiko Segawa, Shusa Ohshika, Naritomo Miyake und 12 weitere

Modern Pathology · 2024

DOI: 10.1016/j.modpat.2023.100359 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Modern Pathology, 2024. Verfasst von Toru Odate und 23 weiteren Autor:innen. Beteiligte Einrichtung: Department of Diagnostic Pathology, National Cancer Center Hospital, Tokyo, Japan. Hauptthemen laut MEDLINE: Rhabdomyosarcoma, Sarcoma, Muscle Neoplasms, Soft Tissue Neoplasms. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 31 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Inflammatory rhabdomyoblastic tumors (IRMTs) are newly recognized skeletal muscle tumors with uncertain malignant potential. We investigated 13 IRMTs using clinicopathologic, genetic, and epigenetic methods. The cohort included 7 men and 6 women, aged 23 to 80 years (median, 50 years), of whom 2 had neurofibromatosis type 1. Most tumors occurred in the deep soft tissues of the lower limbs, head/neck, trunk wall, and retroperitoneum/pelvis. Two tumors involved the hypopharyngeal submucosa as polypoid masses. Eight tumors showed conventional histology of predominantly spindled cells with nuclear atypia, low mitotic activity, and massive inflammatory infiltrates. Three tumors showed atypical histology, including uniform epithelioid or plump cells and mitotically active histiocytes. The remaining 2 tumors demonstrated malignant progression to rhabdomyosarcoma; one had additional IRMT histology and the other was a pure sarcoma. All 11 IRMTs without malignant progression exhibited indolent behavior at a median follow-up of 43 months. One of the 2 patients with IRMTs with malignant progression died of lung metastases. All IRMTs were positive for desmin and PAX7, whereas myogenin and MyoD1 were expressed in a subset of cases. Targeted next-generation sequencing identified pathogenic mutations in NF1 (5/8) and TP53 (4/8). All TP53 mutations co-occurred with NF1 mutations. TP53 variant allele frequency was much lower than that of NF1 in 2 cases. These tumors showed geographic (subclonal) strong p53 immunoreactivity, suggesting the secondary emergence of a TP53-mutant clone. DNA methylation-based copy number analysis conducted in 11 tumors revealed characteristic flat patterns with relative gains, including chromosomes 5, 18, 20, 21, and/or 22 in most cases. Widespread loss of heterozygosity with retained biparental copies of these chromosomes was confirmed in 4 tumors analyzed via allele-specific profiling. Based on unsupervised DNA methylation analysis, none of the 11 tumors tested clustered with existing reference entities but formed a coherent group, although its specificity warrants further study.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RhabdomyosarcomaSarcomaMuscle NeoplasmsSoft Tissue NeoplasmsNeurofibromatosis 1MaleHumansFemaleBiomarkers, Tumor

Stichwörter der Autor:innen

NF1TP53inflammatory leiomyosarcomainflammatory rhabdomyoblastic tumorrhabdomyosarcoma

Substanzen

Biomarkers, Tumor

Autor:innen und Institutionen

  • Department of Diagnostic Pathology, National Cancer Center Hospital, Tokyo, Japan.
  • Department of Diagnostic Pathology, National Cancer Center Hospital, Tokyo, Japan; Department of Pathology, Kyorin University Faculty of Medicine, Tokyo, Japan.
  • Department of Clinical Genomics, National Cancer Center Research Institute, Tokyo, Japan.
  • Department of Brain Disease Translational Research, Juntendo University Graduate School of Medicine, Tokyo, Japan; Division of Brain Tumor Translational Research, National Cancer Center Research Institute, Tokyo, Japan.
  • Division of Cellular Signaling, National Cancer Center Research Institute, Tokyo, Japan.
  • Department of Anatomic Pathology, Hirosaki University Graduate School of Medicine, Aomori, Japan.

Zitieren

APA

Odate, T., Satomi, K., Kubo, T., Matsushita, Y., Ueno, T., Kurose, A., Shomori, K., Nakai, T., Watanabe, R., Segawa, K., Ohshika, S., Miyake, N., Kudo, S., Shimoi, T., Kobayashi, E., Komiyama, M., Yoshimoto, S., Nakatani, F., Kawai, A., …, & Yoshida, A. (2024). Inflammatory Rhabdomyoblastic Tumor: Clinicopathologic and Molecular Analysis of 13 Cases. Modern Pathology. https://doi.org/10.1016/j.modpat.2023.100359

Vancouver

Odate T, Satomi K, Kubo T, Matsushita Y, Ueno T, Kurose A, et al. Inflammatory Rhabdomyoblastic Tumor: Clinicopathologic and Molecular Analysis of 13 Cases. Modern Pathology. 2024. doi:10.1016/j.modpat.2023.100359

BibTeX
@article{Odate2024,
  author = {Odate, Toru and Satomi, Kaishi and Kubo, Takashi and Matsushita, Yuko and Ueno, Toshihide and Kurose, Akira and Shomori, Kohei and Nakai, Tokiko and Watanabe, Reiko and Segawa, Keiko and Ohshika, Shusa and Miyake, Naritomo and Kudo, Sayaka and Shimoi, Tatsunori and Kobayashi, Eisuke and Komiyama, Motokiyo and Yoshimoto, Seiichi and Nakatani, Fumihiko and Kawai, Akira and Yatabe, Yasushi and Kohsaka, Shinji and Ichimura, Koichi and Ichikawa, Hitoshi and Yoshida, Akihiko},
  title = {Inflammatory Rhabdomyoblastic Tumor: Clinicopathologic and Molecular Analysis of 13 Cases},
  journal = {Modern Pathology},
  year = {2024},
  doi = {10.1016/j.modpat.2023.100359}
}
Kostenlos starten →